Biltmore Family Office LLC Has $346,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Biltmore Family Office LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 5.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,771 shares of the company’s stock after acquiring an additional 85 shares during the period. Biltmore Family Office LLC’s holdings in Zoetis were worth $346,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of ZTS. Cetera Investment Advisers increased its holdings in shares of Zoetis by 275.2% during the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock worth $16,259,000 after purchasing an additional 70,476 shares during the period. Simplify Asset Management Inc. bought a new position in Zoetis during the 3rd quarter worth $11,684,000. Soltis Investment Advisors LLC acquired a new position in Zoetis in the 1st quarter valued at $688,000. Bank Pictet & Cie Asia Ltd. lifted its position in shares of Zoetis by 41.0% during the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock valued at $6,501,000 after acquiring an additional 10,900 shares during the period. Finally, Swedbank AB grew its holdings in shares of Zoetis by 56.2% during the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after purchasing an additional 700,398 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Stock Up 0.6 %

Shares of ZTS opened at $176.71 on Friday. The stock has a market capitalization of $79.73 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 2.69 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a fifty day moving average of $185.90 and a 200-day moving average of $180.45.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the company earned $1.36 earnings per share. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.